Neo-adjuvant dovitinib in patients with hepatocellular carcinoma prior to local treatment: a phase II study.

Trial Profile

Neo-adjuvant dovitinib in patients with hepatocellular carcinoma prior to local treatment: a phase II study.

Recruiting
Phase of Trial: Phase II

Latest Information Update: 18 Oct 2012

At a glance

  • Drugs Dovitinib (Primary)
  • Indications Liver cancer
  • Focus Adverse reactions; Biomarker; Pharmacogenomic; Therapeutic Use
  • Acronyms Neo-adjuvant dovitinib in HCC
  • Most Recent Events

    • 16 Nov 2011 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top